墨西哥普遍孕产妇免疫后婴儿百日咳发病与死亡趋势:生态数据库时间序列研究
本研究基于墨西哥IMSS和ISSSTE数据库,分析2010-2018年婴儿百日咳发病、住院和死亡趋势,比较孕产妇Tdap免疫实施前(2010-2012)与实施后(2014-2018)的变化。结果显示,0-2月龄婴儿发病、住院和死亡均显著下降;0-12月龄婴儿住院和死亡下降但发病上升,可能与诊断和报告变化有关。
要点
- 孕产妇Tdap免疫实施后,0-2月龄婴儿百日咳发病、住院和死亡显著下降。
- 0-12月龄婴儿住院和死亡下降,但发病上升,可能受诊断和报告变化影响。
- 研究支持孕产妇Tdap免疫对减少婴儿严重百日咳疾病负担的重要作用。
核心结论
- 孕产妇Tdap免疫实施后,0-2月龄婴儿百日咳发病、住院和死亡呈下降趋势。
- 0-12月龄婴儿发病增加可能与研究期间诊断和报告的重大变化以及部分州疫苗接种和卫生覆盖有限有关。
- 研究结果证实孕产妇Tdap免疫规划对减少墨西哥婴儿百日咳疾病负担、尤其严重疾病的重要贡献。
研究设计与样本
- 生态回顾性数据库研究,数据来自墨西哥国家和社会保障研究所(IMSS;ISSSTE)。
- 收集确诊百日咳门诊病例、住院和死亡数据,以及Tdap和DTPa疫苗接种覆盖率和人口估计。
- 对孕产妇Tdap免疫实施前(2010-2012)与实施后(2014-2018)婴儿百日咳发病和死亡进行描述性和回归时间趋势分析。
主要发现
- 2013年以来,年度孕产妇Tdap疫苗覆盖率范围为70%-93%。
- 2010-2018年间,婴儿中报告2024例百日咳病例、2518例住院和71例死亡。
- 0-2月龄婴儿(孕产妇免疫目标人群)在孕产妇免疫后百日咳发病率显著下降49.9%(p < 0.000),住院下降70.0%(p < 0.000),死亡下降82.4%(p = 0.003)。
- 0-12月龄婴儿百日咳住院下降28.9%(p = 0.000),死亡下降36.2%(p = 0.059),但发病率增加61.8%(p = 0.000)。
临床怎么用
- 可将孕产妇Tdap免疫作为减少小月龄婴儿百日咳严重疾病负担的公共卫生策略。
- 监测婴儿百日咳发病趋势时需考虑诊断和报告标准变化的影响。
局限性
- 生态研究设计,无法推断个体水平因果关系。
- 0-12月龄婴儿发病增加可能受诊断和报告变化及部分州疫苗接种和卫生覆盖有限影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pertussis is a highly contagious infectious disease caused by Bordetella pertussis and a leading cause of infant mortality in Mexico. The Tetanus-diphtheria-acellular pertussis (Tdap) vaccine was recommended in the Mexican Immunisation Programme for pregnant women in 2013. We describe pertussis morbidity and mortality trends in infants ≤2 and ≤12 months of age), before and after maternal Tdap immunisation implementation in Mexico. METHODS: An ecological retrospective database study was performed in the Mexican National and Workers Social Security Institutes (IMSS; ISSSTE). Data were collected on confirmed pertussis ambulatory cases, hospitalisations, and deaths, plus vaccination coverage (Tdap; Diphtheria-tetanus-acellular pertussis [DTPa]) and population estimates. Descriptive and regression time-trend analyses were performed for pertussis morbidity and mortality in infants between pre- (2010-2012) and post- (2014-2018) maternal Tdap immunisation periods. RESULTS: Around 1 million infants a year are covered in IMSS/ISSSTE databases. Average full primary infant DTPa vaccine coverage was 71.4%-72.7% nationally. Since 2013, annual maternal Tdap vaccine coverage ranged from 70%-93%. Between 2010-2018, 2,024 pertussis cases, 2,518 hospitalisations and 71 deaths were reported in infants. Among infants 0-2 months old (maternal immunisation target group), there was a significant decrease, post-maternal vaccination, in pertussis incidence (49.9%, p < 0.000), hospitalisation (70.0%, p < 0.000) and mortality (82.4%, p = 0.003). In infants 0-12 months old, pertussis hospitalisations (28.9%, p = 0.000) and mortality (36.2%, p = 0.059) decreased, but incidence increased (61.8%, p = 0.000). CONCLUSION: After maternal immunisation was implemented, there was a decreasing trend in incidence, hospitalisation and death due to pertussis in infants 0-2 months old. Increases in incidence reported in 0-12-month-olds are likely due to major changes in diagnosis and reporting introduced during the study period as well as limited vaccination and health coverage in some states. These findings confirm the important contribution of the Tdap maternal immunisation programme in reducing pertussis disease burden, particularly severe disease, among infants in Mexico.
引用
- Guzman-Holst A, Luna-Casas G, Cervantes-Apolinar MY, et al. Pertussis infant morbidity and mortality trends after universal maternal immunisation in Mexico: An ecological database study with time-series analysis. Vaccine. 2021. PMID: 33773845. doi:10.1016/j.vaccine.2021.02.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。